In the expanding field of molecular biology and peptide chemistry, few compounds have attracted as much interest from research laboratories as CJC-1295. This synthetic peptide, engineered as a modified analogue of growth hormone‑releasing hormone (GHRH), offers scientists a powerful tool to investigate the somatotropic axis, protein‑bound peptide kinetics, and novel strategies for extending peptide half‑life. Unlike traditional GHRH fragments that are rapidly cleared from circulation, CJC‑1295 was designed with a unique biochemical feature that dramatically alters its pharmacokinetic profile, making it especially valuable for controlled in‑vitro experiments and long‑duration signalling studies. For academic and commercial laboratories across the United Kingdom, understanding the molecular underpinnings, handling requirements, and quality benchmarks of this high‑purity research peptide is essential to achieving reproducible and meaningful data.
At its core, CJC‑1295 is more than just a secretagogue; it represents a case study in peptide engineering. The deliberate attachment of a reactive maleimidopropionic acid linker to the lysine residue at position 15 allows the peptide to form a covalent bond with circulating albumin after being introduced into a biological matrix. This bioconjugation creates a stable peptide‑albumin complex that resists rapid enzymatic degradation and renal clearance, effectively stretching the molecule’s functional lifetime far beyond that of native GHRH or its simpler analogues. Researchers investigating pulsatile hormone release, receptor desensitisation kinetics, or the cross‑talk between peptide hormones and binding proteins therefore find CJC‑1295 an indispensable molecular probe. Throughout this article, we will examine the structural chemistry, core research applications, and critical sourcing considerations that define CJC‑1295 as a category‑leading research compound—always within the strict framework of laboratory use, no human or clinical application intended.
Understanding the Structural Chemistry and Mechanism of CJC‑1295
CJC‑1295 is a 30‑amino acid peptide whose sequence is derived from the first 29 residues of human GHRH, with strategic modifications that transform its behaviour in solution. The foundation is the GHRH(1‑29)‑NH₂ fragment, already known to retain full biological activity through the GHRH receptor. To this backbone, four specific amino acid substitutions are made—D‑Ala², Gln⁸, Ala¹⁵, and Leu²⁷—that collectively enhance metabolic stability. The D‑alanine at position 2 protects the peptide from rapid cleavage by dipeptidyl peptidase‑4 (DPP‑4), a major degradation pathway. The replacement of the original lysine at position 15 with alanine removes a potential protease‑sensitive site, while the other substitutions contribute to a more robust tertiary conformation. However, the truly defining feature of CJC‑1295 is not found in its primary amino acid chain alone but in the Drug Affinity Complex (DAC) technology appended to the newly freed lysine at position 15. Here, a maleimidopropionic acid group is covalently tethered, creating what scientists often refer to as CJC‑1295 with DAC.
The maleimide moiety functions as a selective chemical hook. When the peptide is introduced into plasma or other albumin‑containing biological media, the maleimide ring rapidly reacts with the free thiol group of cysteine‑34 on serum albumin. This nucleophilic addition results in a stable, irreversible thioether bond. The resultant peptide‑albumin conjugate maintains the receptor‑binding domain of CJC‑1295 fully exposed, allowing it to engage the ghrelin/growth hormone secretagogue receptor family and, most importantly, the GHRH receptor on somatotroph cells. Because albumin has a circulatory half‑life measured in weeks, the conjugated peptide inherits a dramatically prolonged presence. For the laboratory scientist, this mechanism unlocks the ability to study sustained receptor activation without the need for continuous peptide infusion. It also provides a model system to examine how large‑carrier molecules alter the biodistribution and intracellular signalling of peptide ligands. These structural insights have sparked numerous in‑vitro protocols that explore dose‑dependent receptor desensitisation, intracellular calcium flux, and cAMP accumulation over extended time courses, well beyond the capabilities of short‑acting GHRH fragments.
From an analytical standpoint, the DAC‑modified CJC‑1295 presents a unique challenge in mass spectrometry and chromatographic purity assessment. The maleimide group is sensitive to hydrolysis at a pH above 7, gradually converting to a ring‑opened maleamic acid form that cannot conjugate to albumin. High‑performance liquid chromatography (HPLC) monitoring of this integrity, typically at a wavelength of 214‑220 nm, is therefore a cornerstone of quality verification. Reputable suppliers test each batch to confirm the presence of a single dominant peak with the expected retention time, often coupled with mass spectrometry to verify the intact molecular weight of approximately 3367.2 Da for the DAC‑containing peptide. The absence of significant impurity peaks is critical, as truncated sequences or oxidized species can yield misleading biological results. This rigorous approach to chemical characterisation ensures that researchers receive a peptide whose structure and reactivity are fully understood, laying the groundwork for reliable in‑vitro experiments.
Key Research Applications and Experimental Design Considerations
In the laboratory, CJC‑1295 is predominantly employed as a probe to interrogate the growth hormone (GH) secretory pathway. Primary pituitary cell cultures, isolated somatotrophs, and engineered cell lines expressing the GHRH receptor are common platforms. By applying the peptide in nanomolar to micromolar concentrations, scientists can measure GH secretion via enzyme‑linked immunosorbent assay (ELISA), track signal transducer and activator of transcription (STAT) signalling cascades, and map the interplay between GHRH receptor activation and other neuroendocrine inputs such as somatostatin or ghrelin. The long‑acting nature of CJC‑1295 with DAC becomes particularly valuable when the experimental objective is to simulate tonic, rather than phasic, receptor stimulation. For example, a 24‑hour exposure study can reveal whether the receptor undergoes homologous desensitisation or whether certain downstream transcription factors remain persistently upregulated, a question of high relevance to understanding growth hormone regulation and metabolic control. These studies are strictly confined to cells, tissues, or biochemical assays; no human or animal administration is implied.
Beyond pituitary‑focused work, CJC‑1295 has found a place in broader investigations of albumin‑binding peptides as a delivery platform. The DAC concept essentially turns a short‑lived peptide into a long‑circulating bioconjugate, a principle that researchers in drug delivery and peptide pharmacology are eager to understand. In vitro models using hepatocyte‑derived cell lines or recombinant albumin solutions allow detailed examination of the maleimide‑albumin conjugation kinetics under different pH and temperature conditions. Such experiments may quantify the second‑order rate constant of the reaction, determine the influence of competing thiol‑containing agents like reduced glutathione, or assess whether the conjugate retains full receptor affinity using surface plasmon resonance (SPR). These data feed into computational models of peptide pharmacokinetics and help refine the design of future peptide‑based probes. The value of CJC‑1295 as a research tool thus extends well beyond endocrinology into chemical biology and bioconjugation chemistry.
Experimental design must account for the peptide’s sensitivity to environmental factors. Before reconstitution, the lyophilised powder is best stored at ‑20°C in a desiccated, light‑protected environment to minimise moisture uptake and preserve the maleimide’s reactivity. Once dissolved in an appropriate solvent—often sterile phosphate‑buffered saline or a mildly acidic buffer (pH 5–6) to stabilise the maleimide—the working solution should be aliquoted and kept at low temperature, with a recommended use within a few weeks to avoid hydrolysis. For cell‑based assays, the addition of low‑endotoxin water and the use of aseptic technique are essential to prevent microbial contamination that could confound results. Researchers frequently include a positive control, such as a known GHRH analogue like sermorelin, and a vehicle control to delineate the specific activity of the CJC‑1295–albumin complex. Because the maleimide reacts rapidly with free cysteines in culture media containing serum, pre‑incubation with serum or albumin and subsequent purification of the conjugate may be advisable for defined studies. These practical considerations, while routine for experienced peptide laboratories, underline the importance of meticulous protocol design when handling reactive peptide therapeutics in a research context.
Sourcing and Handling CJC‑1295 for Reproducible Research Outcomes
The integrity of any laboratory investigation hinges on the quality of the starting materials, and research‑grade peptides demand particular scrutiny. When sourcing CJC‑1295 for in‑vitro work, scientists should expect comprehensive documentation that goes far beyond a basic certificate. A credible supplier will provide a batch‑specific Certificate of Analysis (COA) containing the results of analytical HPLC, which confirms purity—typically expressed as area‑% at a single wavelength—and often a mass spectrum verifying the molecular weight. The HPLC chromatogram should display a sharp, symmetrical main peak with minimal adjacent impurity peaks, indicating a pure product free of deletion sequences or incomplete deprotection side products. Furthermore, identity confirmation through tandem mass spectrometry (MS/MS) sequencing or amino acid analysis adds an extra layer of confidence that the correct peptide has been synthesised. Cjc 1295 that is supplied with independent third‑party testing data, including screens for heavy metals and endotoxins, provides additional assurance. While the United Kingdom does not mandate a pharmacopoeial standard for research peptides, top‑tier suppliers voluntarily adopt these rigorous measures to support reproducible science.
Handling protocols after receipt are equally critical. Upon arrival, the vial should be inspected for cake integrity and absence of foreign particles. The peptide is typically supplied as a trifluoroacetate (TFA) salt, which is hygroscopic; therefore, equilibrating the sealed vial to ambient temperature before opening prevents condensation. Reconstitution under a laminar flow hood using a sterile syringe and solvent that matches the downstream assay is the standard practice. For CJC‑1295 with DAC, the choice of solvent can influence maleimide stability. Many protocols employ a 0.1% acetic acid solution or similar mildly acidic buffer to maintain the maleimide in its reactive, ring‑closed form. Once reconstituted, gentle swirling—never vigorous shaking—dissolves the peptide without creating foam that could denature the molecule. Aliquots should be prepared immediately and stored at ‑80°C for long‑term stability, while a single working aliquot can be kept at 4°C for short‑term use, provided that repeated freeze‑thaw cycles are avoided.
Finally, meticulous record‑keeping and batch management underpin reproducible research. Every experiment using CJC‑1295 should log the batch number, date of reconstitution, solvent composition, and storage conditions. This documentation becomes invaluable if results vary between runs, as it allows the scientist to trace whether a loss of biological activity correlates with a particular handling deviation or an older batch. Laboratories conducting long‑term projects may choose to order multiple vials from the same synthesis batch to minimise inter‑batch variability. In all cases, the peptide is intended exclusively for laboratory and analytical use; it is not a therapeutic agent, not to be administered to humans, and not designed for clinical application. By aligning procurement practices with the highest standards of quality verification—encompassing HPLC purity, mass identity, and the absence of contaminants such as heavy metals and endotoxins—research teams across the UK can harness the full potential of CJC‑1295 as a sophisticated molecular tool, confident that the data they generate will withstand peer review and contribute meaningfully to the collective understanding of peptide science.
Belgrade pianist now anchored in Vienna’s coffee-house culture. Tatiana toggles between long-form essays on classical music theory, AI-generated art critiques, and backpacker budget guides. She memorizes train timetables for fun and brews Turkish coffee in a copper cezve.